Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.56 -0.55%

-$0.29 today

Market cap
$3.69B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.28M

Average 1.16M

Income Statement

Follow revenue through to earnings.

Revenue

$7.50M

FY 2025 · Annual

Operating Income

-$373.07M

FY 2025 · Annual

Net Income

-$345.91M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.44M9.43M007.5M
Cost of Revenue00167.51M2.56M2.54M
Gross Profit18.44M9.43M(167.51M)(2.56M)4.96M
Gross Margin100.0%100.0%——66.1%
Research & Development75.46M105.77M167.51M210.39M300.94M
Selling, General & Admin21.97M32.81M46.54M68.9M79.63M
Operating Expenses97.43M138.58M46.54M276.74M378.03M
Depreciation & Amortization906K1.41M3.54M2.56M2.54M
EBITDA(78.09M)(127.74M)(210.51M)(235.86M)(342.35M)
EBITDA Margin-423.5%-1354.0%——-4564.7%
Operating Income(78.99M)(129.14M)(214.05M)(279.3M)(373.07M)
Operating Margin-428.4%-1368.9%——-4974.3%
Interest Income466K8.71M27.62M41.94M26.83M
Interest Expense00000
Other Income / Expenses105K3.89M31.37M40.88M28.18M
Income Before Tax(78.89M)(125.26M)(182.69M)(238.42M)(344.89M)
Pre-Tax Margin-427.9%-1327.7%——-4598.6%
Income Tax Expense(6K)118K(292K)(4.09M)1.02M
Net Income(78.88M)(125.37M)(182.39M)(234.33M)(345.91M)
Net Margin-427.8%-1328.9%——-4612.1%
EPS (Basic)(1.77)(2.06)(2.73)(3.01)(4.36)
EPS (Diluted)(1.77)(2.06)(2.73)(3.01)(4.36)
Weighted Avg Shares43.63M60.54M66.89M77.89M79.25M
Weighted Avg Shares (Diluted)43.63M60.54M66.89M77.89M79.25M

XENE Earnings Waterfall · TTM

NASDAQ:XENE · Revenue to Net Income

Key Ratios

EPS$-4.70
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-10.7
P/S Ratio0.0

Analysis

$0 of revenue converted into -$428.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.70, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
S-8S-8 filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
SC 13GSC 13G filingNov 6, 2026

How much revenue does XENE generate?

Xenon Pharmaceuticals Inc. (XENE) reported $7.50M of revenue in fiscal 2025.

Is XENE profitable?

Xenon Pharmaceuticals Inc. (XENE) reported -$345.91M of net income, with a net margin of -4612.1%.